Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase

Francis J. Giles*, Eric J. Feldman, Gail J. Roboz, Richard A. Larson, Steven W. Mamus, Jorge E. Cortes, Srdan Verstovsek, Stefan Faderl, Moshe Talpaz, Miloslav Beran, Maher Albitar, Susan M. O'Brien, Hagop M. Kantarjian

*Corresponding author for this work

Research output: Contribution to journalArticle

20 Scopus citations

Abstract

A phase II study of troxacitabine, a non-natural dioxolane nucleoside L-enantiomer, was conducted in patients with chronic myelogenous leukemia in blastic phase (CML-BP). Patients were untreated for BP, or treated with imatinib mesylate (IM) as sole prior therapy for BP. Troxacitabine was given as an intravenous infusion over 30min daily for 5 days at a dose of 8.0mg/m2 per day. Thirty-one patients, 29 (93%) of whom had failed prior IM therapy, received 51 courses of therapy. Grade 3 or 4 toxicities included stomatitis (4%), hand-foot syndrome (18%), and skin rash (12%). Four patients (13%) responded. Troxacitabine-based combinations merit study in IM-resistant CML.

Original languageEnglish (US)
Pages (from-to)1091-1096
Number of pages6
JournalLeukemia Research
Volume27
Issue number12
DOIs
StatePublished - Dec 1 2003

Keywords

  • Blast phase
  • Chronic myelogenous leukemia
  • Imatinib mesylate
  • Troxacitabine

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase'. Together they form a unique fingerprint.

  • Cite this

    Giles, F. J., Feldman, E. J., Roboz, G. J., Larson, R. A., Mamus, S. W., Cortes, J. E., Verstovsek, S., Faderl, S., Talpaz, M., Beran, M., Albitar, M., O'Brien, S. M., & Kantarjian, H. M. (2003). Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. Leukemia Research, 27(12), 1091-1096. https://doi.org/10.1016/S0145-2126(03)00094-8